Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest

• Κύριοι συγγραφείς: Alexander Egeberg (Συγγραφέας), Denis Jullien (Συγγραφέας), Kristian Gaarn Du Jardin (Συγγραφέας), Diamant Thaçi (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Background Five-year tildrakizumab safety data have been reported as exposure-adjusted incidence rates (EAIRs) of patients with events per 100 patient-years (PYs) of exposure. Objectives To present 5-year safety data from reSURFACE 1/2 phase 3 trials as EAIRs of events per 100 PYs of exposure, and t...